Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. May 15, 2022; 14(5): 973-988
Published online May 15, 2022. doi: 10.4251/wjgo.v14.i5.973
Published online May 15, 2022. doi: 10.4251/wjgo.v14.i5.973
Gene name (known as) | Position and length | Exon number | Encoding mRNA and protein | 5’UTR | CDS | 3’UTR |
EFNA1 (ephrin-A1; B61; EFL1; GMAN; ECKLG) | 1q22; 7024bp | 5 (1..194, 3464..3759, 5682..5693, 5855..5905,6082..7024) | NM_004428.3, 1552bp, NM_182685.2, 1486 bp; NP_004419.2 , 205aa, NP_872626.1, 183 aa | 1..103 | 103..194, 3464..3759, 5682..5693, 5855..5905,6082..7024 | 6192..7024 |
Tumor type | Sample type | Expression | Methods | Prognosis value | Notes | Ref. |
Gastric cancer | Tissues | Increased | RT-PCR | (-) | EFNA1 expression is related to GC stage, depth of invasion, lymph node metastasis and recurrence | Nakamura et al[30], 2005 |
Tissues | Increased | IHC | Poor DSS | (-) | Miyazaki et al[32], 2013 | |
Tissues | Increased | IHC, RT-PCR | Poor DSS | EFNA1 expression is related to TNM and lymph node metastasis | Yuan et al[33], 2009 | |
Tissues | Increased | RT-PCR | (-) | SNP (rs12904G>A) can regulate the expression of EFNA1 and is related to GC susceptibility | Li et al[34], 2014 | |
Tissues | Increased | (-) | (-) | EFNA1 expression increase the susceptibility of GC | Zhu et al[35], 2015 | |
Tissues | Increased | (-) | (-) | EFNA1 expression may be related to GC susceptibility | Lee et al[36], 2015 | |
Tissues | Increased | IHC, RT-PCR | Poor DSS | GMAN up-regulates the expression of EFNA1 and promotes the transfer of GC | Zhou et al[37], 2019 | |
Colorectal cancer | Cells | (-) | (-) | (-) | EFNA1 overexpression can inhibit the growth of HT29 cells | Potla et al[42], 2002 |
Tissues | Increased | IHC, RT-PCR | (-) | The expression of EFNA1 promotes the development of rectal adenocarcinoma to rectal cancer | Shi et al[43], 2012 | |
Tissues | Increased | (-) | (-) | EFNA1 may be used as a diagnostic biomarker for the characteristics of CRC. In addition, the rs12904G/A variant is related to the susceptibility to CRC | Mao et al[44], 2013 | |
Cells | (-) | (-) | (-) | Eck and B61 are co-expressed in the same cell, suggesting the existence of an autocrine loop | Rosenberg et al[46], 1997 | |
Tissues | Increased | RT-PCR | Poor DSS | Decreased survival | Kataoka et al[47], 2004 | |
Cells | Reduced | (-) | Poor DSS | EFNA1 can be used as a prognostic marker for CRC | Robertis et al[48], 2017 | |
Tissues | Increased | RT-PCR | Poor DSS | EFNA1 is an independent prognostic factor for CRC | Yamamoto et al[49], 2013 | |
Serum | Increased | IHC, QRT-PCR | Poor DSS | EFNA1 may be used for the identification of CRC | Lip et al[50], 2008 | |
Hepatocellular carcinoma | Tissues | Increased | RT-PCR | Poor DSS | The high expression of EFNA1 protein is related to histological differentiation, portal vein tumor thrombus and lymph node metastasis | Zhang et al[54], 2007 |
Tissues | Increased | RT-PCR | Poor DSS | EFNA1 is an independent prognostic factor of HCC | Wada et al[55], 2014 | |
Tissues | Increased | IHC | Poor DSS | EFNA1 is involved in the mechanism of AFP induction in HCC | Lida et al[57], 2005 | |
Tissues, Serum | Increased | IHC, RT-PCR | Poor DSS | The expression of EFNA1 is positively correlated with AFP | Cui et al[58], 2010 | |
Esophageal cancer | Tissues | Increased | IHC, RT-PCR | Poor DSS | Decreased survival | Xu et al[59], 2005 |
Tissues | Increased | (-) | Poor DSS | Decreased survival | Chen et al[60], 2019 | |
Cells | Increased | RT-PCR | (-) | High expression of EFNA1 decreased the viability of ESCC cells | Yang et al[61], 2015 |
- Citation: Chu LY, Huang BL, Huang XC, Peng YH, Xie JJ, Xu YW. EFNA1 in gastrointestinal cancer: Expression, regulation and clinical significance. World J Gastrointest Oncol 2022; 14(5): 973-988
- URL: https://www.wjgnet.com/1948-5204/full/v14/i5/973.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i5.973